Acta Scientific Ophthalmology (ISSN: 2582-3191)

Case Report Volume 4 Issue 6

Corneo-Uveal-Retinal Adverse Effects after Single Course of Targeted Anti-Cancer Therapy: Case Report and Review of Literature

Maaly Abdel Halim Abdel Fattah1,2,3*, Tariq Abdulmohsen Al-Anazi2, Sara Sohail Kayali3, Yasser Saleh Almuzaini4 and Faisal Mesfer AlQahtani2

1Ophthalmology Department, Cairo University, College of Medicine, Cairo, Egypt
2Ophthalmology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3Al-Faisal University College of Medicine, Riyadh, Saudi Arabia
4Imam Abdulrahman Bin Faisal University, College of Medicine, Riyadh, Saudi Arabia

*Corresponding Author: Maaly Abdel Halim Abdel Fattah, Ophthalmology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Received: May 15, 2021; Published: May 22, 2021



Oral anti vascular endothelial growth factors therapeutic agents have been evolving rapidly over the last past decades and became one of the great contributors to advancement of cancer therapy and increasing survival rate of the treated patients.

Sorafenib is FDA approved medications for the treatment of solid tumors.

In this article, we reported the clinical features of the first Saudi patient presenting with corneo-uveal retinal adverse effects with subsequent bilateral irreversible blindness.

Keywords: Hepatocellular Carcinoma; Targeted Anti-Cancer Therapy; Sorafenib; Oral Anti-Vascular Endothelial Growth Factor; Ocular Toxicity; Irreversible Blindness



  1. Siegel RL., et al. “Cancer statistics, 2020”. CA: A Cancer Journal for Clinicians 1 (2020): 7-30.
  2. Rehman FU., et al. “Anticancer therapeutics: a brief account on wide refinements”. American Journal of Cancer Research 11 (2020): 3599-3621.
  3. Dembic Z. “Antitumor drugs and their targets”. Molecules (2020).
  4. Dalvin LA., et al. “Checkpoint Inhibitor Immune Therapy: systemic indications and ophthalmic side effects”. Retina6 (2018): 1063-1078.
  5. Fortes BH., et al. “Ophthalmic adverse effects of immune checkpoint inhibitors: The Mayo Clinic experience”. British Journal of Ophthalmology (2020).
  6. Roberts PJ and Der CJ. “Targeting the Raf -MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer”. Oncogene 26 (2007): 3291-310.
  7. King J., et al. “Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit”. Journal of Clinical Oncology 4 (2017): 256-262.
  8. Imperia PS., et al. “Ocular complications of systemic cancer chemotherapy”. Survey of Ophthalmology 34 (1989): 209-230.
  9. Fortes BH., et al. “Ocular Toxicity of Targeted Anticancer Agents”. Drugs (2021).
  10. FT Fraunfelder. “FW Fraunfelder”. Journal of Ocular Pharmacology and Therapeutics (2018).
  11. Harman LE. “Ophthalmic complications related to chemotherapy in medically complex patients”. Cancer Control 23 (2016): 150-156.
  12. Wegner A and Khoramnia R. “Neurosensory retinal detachment due to sunitinib treatment”. Eye 25 (2011): 1517-1518.
  13. Hasan R. “A retinal tear induced by pazopanib therapy: a case report”. Medical Education Forum 16 (2015): 1-3.
  14. Gaertner KM., et al. “A case of retinal tear associated with use of sorafenib”. Frontiers in Oncology 4 (2014): 1-2.
  15. Bhatia S., et al. “Phase II trial of sorafenib in combination with carboplastin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512”. PLoS ONE 11 (2012): e48787.
  16. Li ZY., et al. “Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib”. Oncotarget 23 (2016): 35181-35187.
  17. Szczepanik S and Kecik D. “Bilateral central retinal vein occlusion in a patient with disseminated metastatic renal cell carcinoma treated with sorafenib”. Retinal Cases and Brief Reports 2 (2012): 148-150.
  18. Hussain SZ., et al. “Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib”. BMC Endocrine Disorders 13 (2013): 29.


Citation: Maaly Abdel Halim Abdel Fattah., et al. “Corneo-Uveal-Retinal Adverse Effects after Single Course of Targeted Anti-Cancer Therapy: Case Report and Review of Literature".Acta Scientific Ophthalmology 4.6 (2021): 69-75.


Acceptance rate35%
Acceptance to publication20-30 days
ISI- IF1.042
JCR- IF0.24

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US